TGFB1 and neoplasm: IL-13 induced transforming growth factor beta (TGF-β) production by the CD11b+Gr1+ population of myeloid suppressor cells, and blocking TGF-β or depleting Gr1+ cells in vivo could inhibit the suppression of tumor immunity by type II NKT cells (47) (Figure 2).